Artera and Tempus are collaborating to expand access to Artera’s AI-based prostate cancer test. Currently connected to more ...

combined with Tempus' clinical reach and comprehensive real-world data, is designed to achieve important milestones in precision oncology: Enhance precision biomarker prediction and personalized care: ...

Initially, Tempus AI's main initial focus has been on cancer research or oncology, where it has established business ties with roughly 2,500 institutions. According to its investor presentation ...

IFLI is committed to supporting advances in understanding the biology of FL patients who are at high risk of cancer progression and enhancing therapeutic development to address critical unmet needs in ...

CHICAGO, February 03, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has ...

Accordingly, this deal will expand Tempus’s operations in genetic testing for hereditary conditions in oncology and cardiology specialties, among other areas. One of the benefits Ambry will ...

Up about 12%, Tempus AI (NASDAQ:TEM) has been explosive. Helping, its volume just spiked to 18.6 million shares, as compared to its daily average volume of about 5.67 million. All thanks to three ...

In this article, we are going to take a look at where Tempus AI Inc. (NASDAQ:TEM) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as ...